We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+3.01%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$367M
AUM Growth
-$150M
Cap. Flow
-$32.5M
Cap. Flow %
-8.86%
Top 10 Hldgs %
78.79%
Holding
53
New
7
Increased
9
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$8.62M
2
NVO
Novo Nordisk
NVO
+$6.67M
3
VKTX icon
Viking Therapeutics
VKTX
+$4.69M
4
RVMD icon
Revolution Medicines
RVMD
+$4.18M
5
MRUS
Merus
MRUS
+$1.57M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$54.8M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.42M
3
APGE
Apogee Therapeutics
APGE
+$2.3M
4
CRNX
Crinetics Pharmaceuticals
CRNX
+$2.06M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$1.49M

Sector Composition

Rank Sector Weight
1 Healthcare 96.38%
2 Miscellaneous 3.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$200B
$88.3M 24.07%
741,743
+50,000
+7% +$6.67M
LLY icon
2
Eli Lilly
LLY
$1T
$82M 22.36%
92,593
– –
VKTX icon
3
Viking Therapeutics
VKTX
$3.93B
$33.7M 9.2%
532,879
+79,900
+18% +$4.69M
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.8M 4.32%
216,519
– –
AZN icon
5
AstraZeneca
AZN
$248B
$14.9M 4.05%
95,376
– –
SLNO
6
DELISTED
Soleno Therapeutics
SLNO
$13.9M 3.78%
274,424
+180,000
+191% +$8.62M
LLY icon
7
PUT
Eli Lilly
LLY
$1T
$13.3M 3.62%
15,000
-60,000
-80% -$53.9M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$34.8B
$9.63M 2.62%
35,000
– –
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$134B
$8.79M 2.4%
18,900
– –
PCVX icon
10
Vaxcyte
PCVX
$8.98B
$8.71M 2.38%
76,255
– –
ARGX icon
11
argenx
ARGX
$63B
$8.21M 2.24%
15,138
– –
AXSM icon
12
Axsome Therapeutics
AXSM
$10.9B
$7.89M 2.15%
87,848
– –
PTGX icon
13
Protagonist Therapeutics
PTGX
$9.44B
$5.6M 1.53%
124,440
– –
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.8B
$5.18M 1.41%
45,000
– –
RVMD icon
15
Revolution Medicines
RVMD
$44.4B
$4.35M 1.19%
+95,885
New +$4.18M
DYN icon
16
Dyne Therapeutics
DYN
$3.79B
$4.29M 1.17%
119,488
– –
VRNA
17
DELISTED
Verona Pharma
VRNA
$4.27M 1.17%
148,590
+17,800
+14% +$438K
MRUS
18
DELISTED
Merus
MRUS
$4.01M 1.09%
80,171
+30,000
+60% +$1.57M
INSM icon
19
Insmed
INSM
$27.3B
$3.86M 1.05%
52,939
-497
-0.9% -$36.7K
CLDX icon
20
Celldex Therapeutics
CLDX
$3.07B
$2.56M 0.7%
75,300
– –
CRNX
21
DELISTED
Crinetics Pharmaceuticals
CRNX
$2.34M 0.64%
45,765
-40,000
-47% -$2.06M
IDYA icon
22
IDEAYA Biosciences
IDYA
$3.75B
$2M 0.54%
62,992
+8,600
+16% +$326K
MREO
23
Mereo BioPharma
MREO
$40.7M
$1.73M 0.47%
421,359
– –
SWTX
24
DELISTED
SpringWorks Therapeutics
SWTX
$1.73M 0.47%
53,930
– –
NUVL
25
DELISTED
Nuvalent
NUVL
$1.58M 0.43%
+15,437
New +$1.28M
1
2 3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Artia Global Partners held 53 positions worth $367M, down 29% from $517M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Artia Global Partners withdrew a net $32.5M in Q3 2024, closing 8 positions and reducing 5 holdings. Its most notable exit was Merck, an estimated $54.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 75% a quarter earlier, followed by Miscellaneous.

Against the trend, Artia Global Partners opened a new position in Revolution Medicines worth $4.35M.

  • Artia Global Partners's largest Q3 2024 buy was Revolution Medicines: 95,885 shares worth $4.35M.
  • Artia Global Partners added most to Soleno Therapeutics in Q3 2024, an estimated $8.62M increase.
  • Artia Global Partners's biggest Q3 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $2.06M.
  • Artia Global Partners fully exited Merck in Q3 2024, selling an estimated $54.8M.
  • Artia Global Partners's ten largest holdings make up 79% of its $367M portfolio in Q3 2024.
  • Artia Global Partners opened 7 new positions and closed 8 in Q3 2024.
  • Artia Global Partners's portfolio value fell 29% quarter-over-quarter to $367M.

Based on Artia Global Partners's 13F filing for Q3 2024, filed 14 Nov 2024.